The randomized ALLIANCE A051701 trial closed early when treatment-related toxicity and mortality were increased without improving PFS in patients with newly diagnosed double-hit lymphoma.
|Articles|December 7, 2020
Pharmacy Times: Week of December 7 Lineup
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week
Advertisement
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week, including:
- A video interview with Charles Nakar, MD, and Amy Shapiro, MD, both pediatric hematologist-oncologists at the Indiana Hemophilia & Thrombosis Center, on their presentation at the 62nd ASH Annual Meeting and Exposition.
- A new episode of the Pharmacy Focus podcast that discusses the neurological impact of COVID-19 with Daniel R. Wilson, MD, PhD, president of Western University of Health Sciences.
- Ongoing coverage of the American Society of Hematology Annual Meeting and Exposition and the American Society of Health-System Pharmacists Midyear 2020 Clinical Meeting and Exhibition.
Advertisement
Related to this article
Robin Tumlinson, PharmD, BCOP, discusses how rapidly expanding bladder cancer options are creating new questions around treatment sequencing, toxicity management, biomarker testing, and multidisciplinary care.
A prospective observational study found microplastics more frequently and at higher levels in lung samples from patients with lung malignancies, although the findings do not establish that the particles cause cancer.
Helicobacter pylori exposure could be associated with approximately 22% of colorectal cancer cases worldwide.
Eight-year phase 3 ADAURA trial data show adjuvant osimertinib boosts survival in patients with resected EGFR-mutant NSCLC.
Machine-learning and multiple-imputation models could help researchers estimate missing baseline Eastern Cooperative Oncology Group performance status in advanced prostate cancer.
Phase 3 HARMONi-2 interim analysis shows first bispecific PD-1/VEGF antibody outperforming standard immunotherapy in first-line NSCLC.
Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
Advertisement
Advertisement
Trending on Pharmacy Times
1
How Pharmacists Overcome PCSK9 Inhibitor Access Barriers
2
From Reactive to Proactive: AI's Role in Modern Pharmacy Safety
3
Trial Ended Early When Venetoclax Plus DA-EPOCH-R Did Not Improve Outcomes in Double-Hit Lymphoma
4
Pharmacists' Role as Ketone Monitoring Reaches Clinics
5